Gepride M 3 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 3 mg and Metformin 850 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake by tissues. The synergistic action of these two agents helps in achieving better glycemic control in patients inadequately controlled by diet and exercise alone or monotherapy. Gepride M 3 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and regular physical activity. It is essential to monitor blood glucose levels regularly to adjust dosage and prevent hypoglycemia, a potential adverse effect primarily associated with Glimepiride. Metformin is generally well-tolerated but may cause gastrointestinal disturbances and, rarely, lactic acidosis in predisposed individuals. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Patient adherence and periodic assessment of renal function are crucial for safe and effective therapy with Gepride M 3 Tablet PR.